Phaseline

Companies › Vigonvita Life Sciences

Vigonvita Life Sciences: clinical trials, targets and expected readouts

4 active drug programs in 7 registered trials: 6 Phase 1, 1 Phase 2; Other, Psychiatry; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LV232–Phase 2MDDSep 2027
VV913–Phase 1Healthy VolunteersDec 2026
VV119–Phase 1Schizophrenia; Healthy Volunteers–
VV261–Phase 1Healthy Volunteers–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07302269VV261Phase 1Healthy VolunteersOtherJun 2026
NCT07372703VV913Phase 1Healthy VolunteersOtherSep 2026
NCT06504290VV119Phase 1SchizophreniaPsychiatryOct 2026
NCT06105151VV119Phase 1SchizophreniaPsychiatryOct 2026
NCT07240636VV119Phase 1Healthy VolunteersOtherOct 2026
NCT07565792VV913Phase 1Healthy VolunteersOtherDec 2026
NCT06828887LV232Phase 2MDDPsychiatrySep 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Nanjing Minova Pharmaceutical Tortugas Neuroscience Syndeio Biosciences Clear Scientific Basilea Pharmaceutica

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.